Edwards Lifesciences celebrated its 20th anniversary in Singapore on 12 November 2025, highlighting its significant contributions to heart valve therapies in the Asia-Pacific region. The event, held at the company’s Changi facility, underscored Edwards’ commitment to innovation and talent development in collaboration with Singapore’s medical technology ecosystem.
Since its establishment in 2005, Edwards’ Singapore operations have been pivotal in addressing the growing demand for heart valve treatments, crucial in a region where cardiovascular disease accounts for over half of global deaths. Joseph Nuzzolese, Corporate Vice President of Edwards Lifesciences, praised Singapore’s partnership, stating, “The expertise and dedication of our local team, together with Singapore’s strong innovation and talent ecosystem, have been central to our success.”
The celebration also featured remarks from Goh Wan Yee, Senior Vice President and Head of Healthcare at the Singapore Economic Development Board, who acknowledged Edwards’ ongoing commitment to talent and innovation. “Edwards Lifesciences’ continued commitment to deepen talent development and innovation partnerships here is a testament to the global competitiveness of Singapore’s MedTech ecosystem,” she said.
The anniversary marks a milestone in Edwards’ journey of improving patient access to life-saving heart valve treatments across the region. As the company looks to the future, it aims to continue its collaboration with Singapore to advance heart valve innovation, further strengthening its position as a leader in structural heart innovation.
